QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News

$1.04
+0.02 (+1.96%)
(As of 10/3/2023 ET)
Compare
Today's Range
$0.96
$1.04
50-Day Range
$1.02
$2.01
52-Week Range
$0.96
$3.79
Volume
2.51 million shs
Average Volume
1.45 million shs
Market Capitalization
$254.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
284.6% Upside
$4.00 Price Target
Short Interest
Bearish
7.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.31mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$24,840 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.85) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

899th out of 966 stocks

Pharmaceutical Preparations Industry

411th out of 441 stocks


LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

LXRX Price History

LXRX Stock News Headlines

Med-Tech Stock Set To Rally!
With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!
Med-Tech Stock Set To Rally!
With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!
10 Healthcare Stocks with Insider Buying
LXRX - Lexicon Pharmaceuticals, Inc.
LXRX Lexicon Pharmaceuticals, Inc.
LXRX Jan 2024 3.000 put
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
135
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+284.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-101,940,000.00
Net Margins
-32,038.97%
Pretax Margin
-32,038.97%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$0.62 per share

Miscellaneous

Free Float
228,270,000
Market Cap
$254.73 million
Optionable
Optionable
Beta
1.28

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Lonnel Coats (Age 58)
    CEO & Director
    Comp: $1.22M
  • Mr. Jeffrey L. Wade J.D. (Age 58)
    Pres & CFO
    Comp: $788.65k
  • Mr. Brian T. Crum (Age 49)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $609.1k
  • Dr. Kenneth B. Kassler-Taub M.D. (Age 66)
    Sr. VP of Regulatory Affairs & Quality Assurance
    Comp: $588.7k
  • Dr. Craig B. Granowitz M.D. (Age 58)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $671.14k
  • Dr. Robert J. Lefkowitz M.D. (Age 79)
    Consultant & Independent Director
    Comp: $50k
  • Ms. Kristen L. Alexander (Age 54)
    VP of Fin. & Accounting
  • Carrie Siragusa
    Exec. Director of Corp. Strategy and Investor Relations
  • Chas Schultz
    Exec. Director of Corp. Communications & Patient Advocacy
  • Ms. Wendy E. McDermott (Age 52)
    VP of HR













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

1 Wall Street analysts have issued 12 month target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2023?

Lexicon Pharmaceuticals' stock was trading at $1.91 on January 1st, 2023. Since then, LXRX stock has decreased by 45.5% and is now trading at $1.04.
View the best growth stocks for 2023 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The biopharmaceutical company earned $0.32 million during the quarter, compared to analyst estimates of $0.30 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 97.63% and a negative net margin of 32,038.97%.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $1.04.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $254.73 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Lexicon Pharmaceuticals have?

The company employs 135 workers across the globe.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -